Nanox Imaging

A Nanox imaging machine
By  Emily Olsen 06:48 pm August 10, 2021
Digital x-ray imaging company Nanox announced plans to acquire two companies Tuesday, Zebra Medical Vision and USARAD Holdings. Nanox said it entered into an agreement to acquire AI developer Zebra Medical Vision in an all-stock transaction for $100 million upfront and then another $100 million tied to performance.  Nanox also signed a binding letter of intent to acquire teleradiology provider...
Nanox
By  Laura Lovett 12:25 pm April 2, 2021
Israeli imaging startup Nanox has landed FDA clearance for its single-source digital X-ray Nanox.ARC, the company announced today. Nanox came on the imaging scene pitching to lower costs and sell its system via a price-per-scan model. The company’s system combines an in-hospital scanning device with a companion cloud software tool. The X-ray device, which just landed the single-source clearance,...
A mock-up of the Nanox.ARC prototype.
By  Dave Muoio 02:45 pm December 3, 2020
Put your X-ray where your mouth is. After fielding accusations of fraud that temporarily damaged the value of its stock, digital X-ray-imaging company Nanox gave a highly publicized live (but virtual) demonstration of its imaging technology at the Radiology Society of North America's annual meeting. The demo – a recording of which Nanox said will be available to the public later today from the...
Paperwork is handed off between two people
By  Dave Muoio 03:17 pm October 29, 2020
This morning Israeli "Digital X-ray" company Nanox announced a new deal with medical data and image management firm Ambra Health. The agreement will see Ambra's cloud software integrated with the digital component of Nanox's in-development imaging systems, and according to the companies will streamline image management while making it easier to access for providers and patients. "It is our intent...
By  Dave Muoio 03:35 pm September 16, 2020
Israeli "digital X-ray" company Nanox is fielding increased scrutiny and a sizable hit to its share prices following the publication of a scathing report and commentary that referred to the company as "Theranos 2.0." The criticism was posted yesterday by activist short seller Andrew Left's Citron Research, an online stock analysis and commentary blog that has focused on identifying overpriced or...